Form PTO-1449 Docket Number (Optional) Application Number 3837.1US To be assigned INFORMATION DISCLOSURE CITATION 091901,836 Applicant Valerio et al. IN AN APPLICATION (Use several sheets if necessary) Filing Date July 10, 2001 Group Art Unit 🍒 assigned **U.S. PATENT DOCUMENTS EXAMINER** DOCUMENT DATE FILING DATE NAME CLASS SUBCLASS #6,033,908 3/7/00 Bout et al. #6,040,174 3/21/00 Imler et al. FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS **8UBCLASS** NO AMD #FR26491<u>19</u> 1/4/91 France #EPO496074 7/29/92 Europe #WO/9222332 12/23/92 wo #W0/9309221 5/13/93 wo #W0/9416734 8/4/94 WO #WO/9412626 6/9/94 wo #WO/9526412 10/5/95 wo 1ma #W0/9700326 1/3/97 PCT OTHER DOCUMENTS finaluding Author, Title, Date, Pertinent Pages, Etc.) tma #Boado, R.J. (1995) Adv. Drug Deliv. Rev., 15:73-107. #Curiel et al. (1994) Virology, 198:577-585. #Etienne-Julian et al. (1992) J. Gen Virol., (1992) 73: 3251-3255. #Friedmann, T. "Overcoming the obstacles to gene therapy." Sci. Am. June 1997 pp. 96ma #Marin et al. (1994) Gene Therapy, 1(2):s15. Amo DATE CONSIDERED
1/21/04 **EXAMINER** Inne-marie Talk EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

(2-92) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are <u>not</u> being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/000,133 Filed: February 24, 1998

For: METHOD AND MEANS FOR TARGETED GENE DELIVERY which application is being relied upon for an earlier filling date under 35 U.S.C. § 120.

Shest 2 of 2 Form PTO-1449 Docket Number (Optional) **Application Number** 3837.1US To be assigned INFORMATION DISCLOSURE CITATION 091901,836 IN AN APPLICATION Applicant Valerio et al. (Use several sheets if necessary) Filing Date July 10, 2001 Group Art Unit To be essigned 1632 **U.S. PATENT DOCUMENTS** EXAMINER INITIAL DOCUMENT DATE NAME FILING DATE CLASS SUBCI ASS FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) #Nilson et al. (1994) Gene Therapy, 1(2):s17 Amon #Orkin, et al. "Report and recommendations of the panel to assess the NIH investment in ma research on gene therapy." 12/95 #Roux et al. (1989) Proc. Natl. Acad. Sci., 86:9079-9083. #Russell et al. (1993) Nucleic Acids Research, 21(5):1081-1085. #Truong et al. (1993) Proc. Intern. Symp. Control, Release Bioact. Mater., 20: 474-475. Ama #Verma et al. "Gene therapy - promises, problems and prospects. (9/97) Nature 389:239-#Zatloukal et al. (1993) J. Cell Biochem., 17(d):129. Amy DATE CONSIDERED 1/21/04 **EXAMINER** ne-Marie Falk EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP \$ 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

(2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they

vere previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/000,133 Filed: February 24, 1998

For: METHOD AND MEANS FOR TARGETED GENE DELIVERY which application is being relied upon for an earlier filling date under 35 U.S.C. § 120.